Hormone Therapy Improves Survival of Low Grade Serous Carcinoma Patients

A team from University of Texas MD Anderson Cancer Center, including OCRFA Scientific Advisory Committee Member Dr. Robert Coleman, published a study in Journal of Clinical Oncology about the effect of hormonal therapy on a rare type of ovarian cancer. The use of hormone maintenance therapy (HMT) with low-grade serous carcinoma (LGSC), a subtype of epithelial ovarian or peritoneum cancer, was found to significantly improve both profession free survival and overall survival.